Product Description
BlueSphere’s TCX-101 program combines an engineered TCR T-cell therapy targeting a blood restricted antigen with allogeneic stem cell transplant. Our goal is to create a best-in-class HLA population coverage panel of novel TCR T-cell therapies for treatment of AML, ALL, and MDS. (Sourced from: https://bluespherebio.com/clinical-programs/tcx-101/)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BlueSphere
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Hematological Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|